2019 ESC Guidelines for the management of patients with supraventricular tachycardia
This guideline cites 3 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2019
- Source
- Brugada J, Katritsis DG, et al. Eur Heart J. 2020;41(5):655–720.doi 10.1093/eurheartj/ehz467
The 2019 ESC guideline puts vagal manoeuvres and adenosine first in the acute termination of supraventricular tachycardia, makes catheter ablation the definitive therapy for symptomatic AVNRT and AVRT, and — importantly — recommends electrophysiological risk stratification rather than blanket ablation in asymptomatic pre-excitation. The randomised evidence in this field is unusually sparse; the three trials below carry a disproportionate share of it.
Acute termination: vagal manoeuvres1
- 2015REVERTCardiology · Arrhythmia · Vagal manoeuvresIn 433 adults presenting to the emergency department with supraventricular tachycardia, a modified Valsalva manoeuvre with supine repositioning and passive leg raise more than doubled cardioversion to sinus rhythm at 1 minute compared with the standard semi-recumbent Valsalva manoeuvre.OR 3.795% CI 2.3-5.8Read →
Pre-excitation & accessory-pathway ablation1
- 2003Pappone WPWCardiology · Arrhythmia · Pre-excitationIn 72 asymptomatic patients with a Wolff-Parkinson-White pattern judged high-risk on electrophysiological testing, prophylactic radiofrequency ablation of the accessory pathway markedly reduced arrhythmic events over 5 years compared with no treatment.RR 0.0895% CI 0.02-0.33Read →
Inappropriate sinus tachycardia1
- 2012Cappato ISTCardiology · Arrhythmia · Inappropriate sinus tachycardiaIn 21 patients with symptomatic inappropriate sinus tachycardia, ivabradine eliminated most symptoms and lowered heart rate at rest, on standing and during exertion compared with placebo.RR 0.2595% CI 0.18-0.34Read →
Cited landmark trials not yet in the register3
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2017Adenosine vs. verapamil meta-analyses
Comparable termination rates; adenosine is faster, verapamil longer-acting.
- 2012Pappone asymptomatic WPW registry
The long-term cohort behind the electrophysiological risk-stratification strategy.
- 2004Flecainide pill-in-the-pocket
Self-administered antiarrhythmic conversion for infrequent, well-tolerated episodes.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.